Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 09, 2022

SELL
$0.21 - $0.53 $6,390 - $16,128
-30,431 Closed
0 $0
Q1 2022

May 17, 2022

BUY
$0.32 - $0.67 $9,737 - $20,388
30,431 New
30,431 $16,000
Q4 2021

Feb 17, 2022

SELL
$0.6 - $1.11 $96,228 - $178,021
-160,380 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$1.01 - $1.82 $76,102 - $137,135
75,349 Added 88.61%
160,380 $164,000
Q2 2021

Sep 17, 2021

SELL
$1.39 - $2.21 $94,096 - $149,605
-67,695 Reduced 44.32%
85,031 $156,000
Q1 2021

May 19, 2021

SELL
$1.27 - $3.42 $1,501 - $4,042
-1,182 Reduced 0.77%
152,726 $301,000
Q4 2020

Feb 24, 2021

BUY
$0.94 - $1.89 $144,673 - $290,886
153,908 New
153,908 $192,000
Q3 2020

Dec 11, 2020

SELL
$1.5 - $9.38 $42,825 - $267,799
-28,550 Closed
0 $0
Q2 2020

Aug 07, 2020

BUY
$4.79 - $8.39 $51,411 - $90,049
10,733 Added 60.24%
28,550 $240,000
Q4 2019

Feb 04, 2020

BUY
$4.29 - $5.64 $76,434 - $100,487
17,817 New
17,817 $97,000
Q3 2019

Nov 20, 2019

SELL
$4.87 - $7.08 $139,574 - $202,912
-28,660 Closed
0 $0
Q2 2019

Aug 13, 2019

BUY
$6.6 - $7.8 $189,156 - $223,548
28,660 New
28,660 $199,000
Q1 2019

Apr 12, 2019

SELL
$5.76 - $8.95 $73,797 - $114,667
-12,812 Closed
0 $0
Q4 2018

Jan 16, 2019

BUY
$5.26 - $7.97 $173 - $263
33 Added 0.26%
12,812 $75,000
Q3 2018

Nov 13, 2018

BUY
$4.65 - $7.95 $59,422 - $101,593
12,779 New
12,779 $96,000
Q2 2018

Jul 30, 2018

SELL
$5.05 - $6.8 $99,171 - $133,538
-19,638 Closed
0 $0
Q2 2018

Jul 30, 2018

BUY
$5.05 - $6.8 $25,830 - $34,782
5,115 Added 35.22%
19,638 $99,000
Q1 2018

May 14, 2018

BUY
$5.6 - $9.25 $81,328 - $134,337
14,523 New
14,523 $89,000

Others Institutions Holding CRBP

About Corbus Pharmaceuticals Holdings, Inc.


  • Ticker CRBP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 125,268,000
  • Market Cap $1.46B
  • Description
  • Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...
More about CRBP
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.